Present in central nervous system and peripheral tissues.
Inhibition of CB1 receptors results in reduced food intake and decreased body weight and causes metabolic effects including increased HDL levels, decreased triglycerides, CRP levels and decreased HgbA1C levels in diabetics.
Rimonabant, a CB1 antagonist reduces body weight and diminishes abdominal obesity and improves metabolic syndrome.
Administration of rimonabant over 18 months did not significantly reduce the primary end point, the rate of progression of coronary artery disease (percentage of atheroma volume), but did decrease total atheroma volume, the secondary endpoint (STRADIVARIUS trial).
Rimonabant a CB1 inhibitor is associated with increased psychiatric and gastrointestinal adverse affects including depression and nausea.
Rimonabant a CB1 inhibitor decreases body weight, waist circumference, increases HDL-C levels and reduces triglycerides levels.